-
Uncategorized1 week agoSTAT+: Why this Stanford psychiatrist thinks diet can influence serious mental health disorders
Health secretary Robert F. Kennedy Jr. made waves in February when he opined that changing your diet can “cure” schizophrenia. His comment sparked a wave of...
-
Uncategorized1 week agoAutism Risk Genes Largely Shared Across Global Populations
Over the past decade, scientists have identified numerous genetic variants that confer substantial risk for autism and other neurodevelopmental disorders. However, most of these discoveries were...
-
Uncategorized1 week ago
After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer
Serial biotech investor Kevin Tang previously unsuccessfully tried to buy Kezar Life Sciences via Concentra Biosciences, a biotech consolidation company owned by the venture capital firm...
-
Uncategorized1 week ago
#ACC26: Merck touts comparator data for oral cholesterol drug
Merck’s drug enlicitide beat a handful of commonly used cholesterol-lowering drugs in a comparator trial, inching it closer to becoming the first oral PCSK9 inhibitor. The...
-
Uncategorized1 week agoLilly’s AI commitment expands through deal with Insilico
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks to sustain its industry lead. Read More
-
Uncategorized1 week ago
Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?
Viridian Therapeutics’ shares dropped Monday morning after a lackluster pivotal readout on its injection to treat thyroid eye disease. Viridian’s pitch is that its drug, known...
-
Uncategorized1 week ago
Blackstone raises $6.3B life sciences fund in record fundraising haul
The life sciences industry’s largest-ever private investment fund has arrived, and it comes from the world’s biggest alternative asset manager. On Monday, Blackstone announced it had...
-
Uncategorized1 week agoSTAT+: Early signs of Alzheimer’s often go undetected. These researchers want to change that
Researchers in Massachusetts are experimenting with artificial intelligence to detect signs of Alzheimer’s disease in its earliest stages, when symptoms of the dreaded illness may go...
-
Uncategorized1 week ago
Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies
Two separate randomized trials failed to illustrate Impella’s benefits in specific cases of patients with blocked coronary arteries.
-
Uncategorized1 week agoEli Lilly and Insilico agree AI-driven drug discovery alliance
Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
